BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 29575058)

  • 1. Amino acids as chiral derivatizing agents for antiproliferative substituted N-benzyl isoindolinones.
    Grigoreva TA; Novikova DS; Gureev MA; Garabadzhiu AV; Tribulovich VG
    Chirality; 2018 Jun; 30(6):785-797. PubMed ID: 29575058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proapoptotic modification of substituted isoindolinones as MDM2-p53 inhibitors.
    Grigoreva TA; Novikova DS; Petukhov AV; Gureev MA; Garabadzhiu AV; Melino G; Barlev NA; Tribulovich VG
    Bioorg Med Chem Lett; 2017 Dec; 27(23):5197-5202. PubMed ID: 29089230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structure-activity studies leading to improved potency.
    Hardcastle IR; Liu J; Valeur E; Watson A; Ahmed SU; Blackburn TJ; Bennaceur K; Clegg W; Drummond C; Endicott JA; Golding BT; Griffin RJ; Gruber J; Haggerty K; Harrington RW; Hutton C; Kemp S; Lu X; McDonnell JM; Newell DR; Noble ME; Payne SL; Revill CH; Riedinger C; Xu Q; Lunec J
    J Med Chem; 2011 Mar; 54(5):1233-43. PubMed ID: 21314128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New chiral derivatizing agents: convenient determination of absolute configurations of free amino acids by 1H NMR.
    Kurosu M; Li K
    Org Lett; 2009 Feb; 11(4):911-4. PubMed ID: 19170578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MDM2-p53 protein-protein interaction inhibitors: a-ring substituted isoindolinones.
    Watson AF; Liu J; Bennaceur K; Drummond CJ; Endicott JA; Golding BT; Griffin RJ; Haggerty K; Lu X; McDonnell JM; Newell DR; Noble ME; Revill CH; Riedinger C; Xu Q; Zhao Y; Lunec J; Hardcastle IR
    Bioorg Med Chem Lett; 2011 Oct; 21(19):5916-9. PubMed ID: 21875801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
    Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L
    Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resolution and isolation of enantiomers of (±)-isoxsuprine using thin silica gel layers impregnated with L-glutamic acid, comparison of separation of its diastereomers prepared with chiral derivatizing reagents having L-amino acids as chiral auxiliaries.
    Bhushan R; Nagar H
    Biomed Chromatogr; 2015 Mar; 29(3):357-65. PubMed ID: 25044026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting of p53 peptide analogues to anti-apoptotic Bcl-2 family proteins as revealed by NMR spectroscopy.
    Shin JS; Ha JH; Chi SW
    Biochem Biophys Res Commun; 2014 Jan; 443(3):882-7. PubMed ID: 24342622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro.
    Krajewski M; Ozdowy P; D'Silva L; Rothweiler U; Holak TA
    Nat Med; 2005 Nov; 11(11):1135-6; author reply 1136-7. PubMed ID: 16270059
    [No Abstract]   [Full Text] [Related]  

  • 10. Structural basis for the conserved binding mechanism of MDM2-inhibiting peptides and anti-apoptotic Bcl-2 family proteins.
    Lee MS; Ha JH; Yoon HS; Lee CK; Chi SW
    Biochem Biophys Res Commun; 2014 Feb; 445(1):120-5. PubMed ID: 24491548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold.
    Hardcastle IR; Ahmed SU; Atkins H; Farnie G; Golding BT; Griffin RJ; Guyenne S; Hutton C; Källblad P; Kemp SJ; Kitching MS; Newell DR; Norbedo S; Northen JS; Reid RJ; Saravanan K; Willems HM; Lunec J
    J Med Chem; 2006 Oct; 49(21):6209-21. PubMed ID: 17034127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of absolute configurations of amines and amino acids using nonchiral derivatizing agents (NCDA) and deuterium NMR.
    Chalard P; Bertrand M; Canet I; Théry V; Remuson R; Jeminet G
    Org Lett; 2000 Aug; 2(16):2431-4. PubMed ID: 10956514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induced folding by chiral nonplanar aromatics.
    Narasimhan SK; Kerwood DJ; Wu L; Li J; Han Y; Zhu S; Shah A; Lombardi R; Freedman TB; Luk YY
    J Org Chem; 2009 Sep; 74(18):7023-33. PubMed ID: 19673472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of the inhibitory mechanism of apomorphine against MDM2-p53 interaction.
    Ishiba H; Noguchi T; Shu K; Ohno H; Honda K; Kondoh Y; Osada H; Fujii N; Oishi S
    Bioorg Med Chem Lett; 2017 Jun; 27(11):2571-2574. PubMed ID: 28400230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring Ligand-Induced Protein Ordering in Drug Discovery.
    Grace CR; Ban D; Min J; Mayasundari A; Min L; Finch KE; Griffiths L; Bharatham N; Bashford D; Kiplin Guy R; Dyer MA; Kriwacki RW
    J Mol Biol; 2016 Mar; 428(6):1290-1303. PubMed ID: 26812210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening of medicinal plant phytochemicals as natural antagonists of p53-MDM2 interaction to reactivate p53 functioning.
    Riaz M; Ashfaq UA; Qasim M; Yasmeen E; Ul Qamar MT; Anwar F
    Anticancer Drugs; 2017 Oct; 28(9):1032-1038. PubMed ID: 28723868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rational design and synthesis of 1,5-disubstituted tetrazoles as potent inhibitors of the MDM2-p53 interaction.
    Surmiak E; Neochoritis CG; Musielak B; Twarda-Clapa A; Kurpiewska K; Dubin G; Camacho C; Holak TA; Dömling A
    Eur J Med Chem; 2017 Jan; 126():384-407. PubMed ID: 27907876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction.
    Zhuang C; Miao Z; Zhu L; Dong G; Guo Z; Wang S; Zhang Y; Wu Y; Yao J; Sheng C; Zhang W
    J Med Chem; 2012 Nov; 55(22):9630-42. PubMed ID: 23046248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and biological evaluation of imidazoline derivatives as p53-MDM2 binding inhibitors.
    Hu C; Li X; Wang W; Zhang L; Tao L; Dong X; Sheng R; Yang B; Hu Y
    Bioorg Med Chem; 2011 Sep; 19(18):5454-61. PubMed ID: 21855354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction.
    Allen JG; Bourbeau MP; Wohlhieter GE; Bartberger MD; Michelsen K; Hungate R; Gadwood RC; Gaston RD; Evans B; Mann LW; Matison ME; Schneider S; Huang X; Yu D; Andrews PS; Reichelt A; Long AM; Yakowec P; Yang EY; Lee TA; Oliner JD
    J Med Chem; 2009 Nov; 52(22):7044-53. PubMed ID: 19856920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.